替雷利珠单抗对复发或转移性鼻咽癌患者健康相关生活质量的影响
本研究基于RATIONALE-309随机对照试验,评估替雷利珠单抗联合化疗对比安慰剂联合化疗在复发或转移性鼻咽癌意向治疗人群及肝转移亚组中的健康相关生活质量。结果显示多数生活质量评分组间无差异,但替雷利珠单抗联合化疗组在QLQ-H&N35疼痛评分及肝转移亚组感觉问题评分方面表现更优。
要点
- 意向治疗人群共263例,替雷利珠单抗联合化疗组131例,安慰剂联合化疗组132例,43%伴肝转移。
- QLQ-C30所选评分从基线至第4或第8周期变化在意向治疗人群及肝转移亚组中组间均无差异。
- 意向治疗人群及肝转移亚组中,替雷利珠单抗联合化疗组QLQ-H&N35疼痛评分从基线至第8周期降低幅度大于安慰剂联合化疗组。
核心结论
- 替雷利珠单抗联合化疗在改善生存及安全性良好的基础上,可能作为复发或转移性鼻咽癌的一线治疗选择。
研究设计与样本
- RATIONALE-309(NCT03924986)随机对照试验,患者按1:1随机分配至替雷利珠单抗联合化疗组或安慰剂联合化疗组。
- 意向治疗人群共263例(替雷利珠单抗联合化疗组n=131,安慰剂联合化疗组n=132),其中43%伴肝转移(替雷利珠单抗联合化疗组n=56,安慰剂联合化疗组n=57)。
- 健康相关生活质量作为次要终点,采用EORTC QLQ-C30及QLQ头颈癌模块(QLQ-H&N35)中七个选定评分评估。
主要发现
- 意向治疗人群及肝转移亚组中,QLQ-C30所选评分从基线至第4周期或第8周期的变化组间均无差异。
- 从基线至第4周期,QLQ-H&N35所选评分组间无差异。
- 意向治疗人群及肝转移亚组中,替雷利珠单抗联合化疗组QLQ-H&N35疼痛评分从基线至第8周期的降低幅度大于安慰剂联合化疗组。
- 肝转移亚组中,第8周期时替雷利珠单抗联合化疗组QLQ-H&N35感觉问题评分改善程度大于安慰剂联合化疗组。
- 组间至恶化时间无差异。
临床怎么用
- 原文结论认为,结合生存获益及良好安全性,替雷利珠单抗联合化疗可能作为复发或转移性鼻咽癌的一线治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study evaluated health-related quality of life (HRQoL) in the RATIONALE-309 (NCT03924986) intent-to-treat (ITT) population and in a subgroup of patients with liver metastases. METHODS: Patients were randomized 1:1 to tislelizumab + chemotherapy or placebo + chemotherapy. As the secondary endpoint, HRQoL was evaluated using seven selected scores from the EORTC QLQ-C30 and QLQ Head and Neck Cancer module (QLQ-H&N35). RESULTS: Of 263 randomized patients in the ITT population (tislelizumab + chemotherapy n = 131, placebo + chemotherapy n = 132), 43% had liver metastases (tislelizumab + chemotherapy n = 56; placebo + chemotherapy n = 57). No differences in change in selected scores on the QLQ-C30 from baseline to cycle 4 or cycle 8 were observed for the ITT or liver metastases subgroup. No differences in selected QLQ-H&N35 scores were observed between the arms from baseline to cycle 4. In the ITT population and the liver metastases subgroup, a greater reduction from baseline to cycle 8 was observed in the tislelizumab + chemotherapy arm than the placebo + chemotherapy arm in QLQ-H&N35 pain score. At cycle 8 in the liver metastases subgroup, the tislelizumab + chemotherapy arm experienced greater improvement in the QLQ-H&N35 senses problems score than the placebo + chemotherapy arm. Differences in time to deterioration between arms were not observed. CONCLUSIONS: The current findings, along with improved survival and favorable safety, suggests that tislelizumab + chemotherapy represents a potential first-line treatment for recurrent or metastatic nasopharyngeal cancer.
引用
- Yang Y, Pan J, Chen N, et al. Effects of tislelizumab on health-related quality of life in patients with recurrent or metastatic nasopharyngeal cancer. Head Neck. 2024. PMID: 38671587. doi:10.1002/hed.27785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。